Skip to content

ACER THERAPEUTICS INC.: 10-Q filed 2011-11-04

What ACER THERAPEUTICS INC. reported in its quarterly report filed 2011-11-04 (fiscal Q3 2011): 23 published measures, 64 facts as tagged in accession 0001157523-11-006466.

This filing

Form
10-Q (quarterly report)
Filed
2011-11-04
Fiscal period
fiscal Q3 2011
Accession
0001157523-11-006466 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ACER THERAPEUTICS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-09-309,698,720USD
At 2010-12-314,714,018USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-09-308,968,270USD
At 2010-12-313,968,713USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-09-308,639,856USD
At 2010-12-313,812,535USD
At 2010-09-304,733,445USD
At 2009-12-318,181,582USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-07-01 to 2011-09-30-1,297,278USD92
2011-01-01 to 2011-09-30-4,091,439USD273
2003-01-22 to 2011-09-30-98,803,778USD3174
2010-07-01 to 2010-09-30-1,290,815USD92
2010-01-01 to 2010-09-30-4,534,292USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-01-01 to 2011-09-30-3,471,212USD273
2003-01-22 to 2011-09-30-48,993,979USD3174
2010-01-01 to 2010-09-30-3,507,767USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2011-01-01 to 2011-09-30284,017USD273
2003-01-22 to 2011-09-301,658,878USD3174

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-01-01 to 2011-09-308,582,550USD273
2003-01-22 to 2011-09-3059,292,713USD3174
2010-01-01 to 2010-09-3059,630USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-01-01 to 2011-09-30-284,017USD273
2003-01-22 to 2011-09-30-1,658,878USD3174

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-09-30953,219USD
At 2010-12-31815,958USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-07-01 to 2011-09-30-1,296,867USD92
2011-01-01 to 2011-09-30-4,089,494USD273
2003-01-22 to 2011-09-30-97,767,928USD3174
2010-07-01 to 2010-09-30-1,289,626USD92
2010-01-01 to 2010-09-30-4,036,487USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-09-308,745,501USD
At 2010-12-313,898,060USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2011-07-01 to 2011-09-30638USD92
2011-01-01 to 2011-09-302,643USD273
2003-01-22 to 2011-09-309,056,467USD3174
2010-07-01 to 2010-09-302,004USD92
2010-01-01 to 2010-09-30499,200USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-09-30730,450USD
At 2010-12-31745,305USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2011-09-30429,565USD
At 2010-12-31358,837USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2003-01-22 to 2011-09-30325USD3174

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-07-01 to 2011-09-30654,772USD92
2011-01-01 to 2011-09-302,194,141USD273
2003-01-22 to 2011-09-3069,032,978USD3174
2010-07-01 to 2010-09-30625,282USD92
2010-01-01 to 2010-09-302,193,919USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-09-3023,048,488shares
At 2010-12-3118,466,924shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2011-09-30107,541,563USD
At 2010-12-3198,496,382USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2011-09-301,222,758USD
At 2010-12-311,109,558USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2011-09-30285,885USD
At 2010-12-31335,861USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-07-01 to 2011-09-30584,794USD92
2011-01-01 to 2011-09-301,737,686USD273
2003-01-22 to 2011-09-3026,940,492USD3174
2010-07-01 to 2010-09-30626,697USD92
2010-01-01 to 2010-09-301,706,546USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2003-01-22 to 2011-09-30661,146USD3174

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-09-3059,817USD273
2003-01-22 to 2011-09-30-16,396USD3174
2010-01-01 to 2010-09-30-140,280USD273

Inspect the source

Entity
ACER THERAPEUTICS INC. / CIK 0001069308
Captured
SEC response SHA-256
d41ecd9c66d537efeeb403c8604fe32734f808b5d83b00a9acc9f0ba72164b38

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001069308.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))